

DRUG PRIOR AUTHORIZATION COMMITTEE

June 19, 2014

TENTATIVE AGENDA

Department of Natural Resources
Lacharrette/Nightengale Rooms
1101 Riverside Dr
Jefferson City MO

10:00 - 10:05	Welcome, Announcements and Introductions	Chairman
10:05 - 10:15	Minutes Review	Discussion/Approval
10:15- 11:15	Pharmacy Program/ Budget Update	Rhonda Driver/Andrew Haslag
11:15 - 11:20	DUR Update	Rhonda Driver
	<u>Old Business</u>	
11:20 – 11:30	A. Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)	Rhonda Driver
	<u>New Business</u>	
11:30 – 11:45	B. Proposed Actions- New Drug/Product Review (See website and Attached Summary) i. Open Access ii. Clinical Edit/Step Therapy iii. PDL Products iv. Prior Authorization <ul style="list-style-type: none">• Discussion• Public Hearing• Decision	Rhonda Driver
11:45 – 1:00	C. <u>Preferred Drug List (PDL)</u> I. Alpha-Glucosidase Inhibitors <ul style="list-style-type: none">• Discussion• Public Hearing• Decision II. Androgen Hormone Inhibitors <ul style="list-style-type: none">• Discussion• Public Hearing• Decision III. Antidiabetic Combination Agents <ul style="list-style-type: none">• Discussion• Public Hearing	

- Decision
- IV. GLP-1 Receptor Agonists**
 - Discussion
 - Public Hearing
 - Decision
- V. Amylin Analogs**
 - Discussion
 - Public Hearing
 - Decision
- VI. Antihyperurecemic Agents**
 - Discussion
 - Public Hearing
 - Decision
- VII. Biguanides**
 - Discussion
 - Public Hearing
 - Decision
- VIII. Bile Salts**
 - Discussion
 - Public Hearing
 - Decision
- IX. Bone Ossification Suppression Agents**
 - Discussion
 - Public Hearing
 - Decision
- X. Cryopyrin Associated Periodic Syndrome Agents**
 - Discussion
 - Public Hearing
 - Decision
- XI. DPP-IV Inhibitor Agents**
 - Discussion
 - Public Hearing
 - Decision
- XII. Electrolyte Depleters**
 - Discussion
 - Public Hearing
 - Decision
- XIII. Growth Hormones**
 - Discussion
 - Public Hearing
 - Decision
- XIV. Hematopoietic Agents**
 - Discussion
 - Public Hearing
 - Decision
- XV. Hepatitis C Agents**
 - Discussion
 - Public Hearing

- Decision
- XVI. Immunomodulators/Biologics Agents**
 - Discussion
 - Public Hearing
 - Decision
- XVII. Insulins**
 - Discussion
 - Public Hearing
 - Decision
- XVIII. Insulins – Long Acting**
 - Discussion
 - Public Hearing
 - Decision
- XIX. Insulins – Rapid Acting**
 - Discussion
 - Public Hearing
 - Decision
- XX. Insulins – Mix**
 - Discussion
 - Public Hearing
 - Decision
- XXI. Macrolides - Adult**
 - Discussion
 - Public Hearing
 - Decision
- XXII. Macrolides - Pediatric**
 - Discussion
 - Public Hearing
 - Decision
- XXIII. Meglitinides**
 - Discussion
 - Public Hearing
 - Decision
- XXIV. Multiple Sclerosis Agents**
 - Discussion
 - Public Hearing
 - Decision
- XXV. Quinolones - Systemic**
 - Discussion
 - Public Hearing
 - Decision
- XXVI. Ribavirans**
 - Discussion
 - Public Hearing
 - Decision
- XXVII. 2nd Generation Sulfonylureas**
 - Discussion
 - Public Hearing
 - Decision

- XXVIII. SGT-2 Inhibitors**
 - Discussion
 - Public Hearing
 - Decision
- XXIX. Tetracyclines**
 - Discussion
 - Public Hearing
 - Decision
- XXX. Thiazolidinediones**
 - Discussion
 - Public Hearing
 - Decision
- XXXI. Urinary Tract Antispasmodics**
 - Discussion
 - Public Hearing
 - Decision
- XXXII. Vaginal Antibiotics**
 - Discussion
 - Public Hearing
 - Decision

E. Preferred Drug List

- i. Process Discussion
- ii. Therapeutic classes/to be announced at meeting

1:00

LUNCH

1:15-1:30

Program Utilization Information-Xerox Update

Rhonda Driver/

Josh Moore

1:30-1:50

Other Business

- *“Top 25” Drugs by Cost/Claims*
- *Clinical Edit Summary Report*
- *Call Center Statistics*

Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, Agenda may move more quickly

Executive Session

1:50-1:55

Minutes Review Discussion/Approval

1:55-2:30

Case Reviews Jenna Twehus

NEXT MEETING: September 18, 2014

Truman Building

Rooms 490/492

301 West High Street

DRAFT